López-Sepúlveda Rocío, García Lirola María Ángeles, Espínola García Esther, Jurado Martínez Jose María, Martín Sances Salvadora, Anaya Ordóñez Sonia, Cabeza Barrera José
Unidad Gestión Clínica de Farmacia Provincial de Granada, Distrito Sanitario Granada Metropolitano, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada, Spain.
Unidad Gestión Clínica de Farmacia Provincial de Granada, Distrito Sanitario Granada Metropolitano, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada, Spain.
Prim Care Diabetes. 2017 Jun;11(3):254-264. doi: 10.1016/j.pcd.2017.01.003. Epub 2017 Jan 23.
There is a widening range of antidiabetic medications available; however changes in consumption patterns remain poorly documented. The aim of this study is to analyze the evolution of consumption of antidiabetic medications during the period 2001-2014 in an Andalusian region.
All antidiabetic medicines on the market were selected for analysis. Consumption data were obtained for the 15-year period and were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DHD).
During the study period consumption of insulins grew only a 2.2%, from 17.9 DHD to 18.3 DHD, while oral agents increased a 27.6%, from 41.3 DHD to 52.7 DHD. Consumption of sulfonylureas was gradually reduced from 30.1 DHD to 16.4 DHD but metformin (alone) usage increased from 4.3 DHD to 23.7 DHD, and was the most consumed agent in 2014. A rise in consumption of dipeptidyl peptidase-4 inhibitors and "other hypoglycemic agents" was also noticed. Overall expenditure in antidiabetic medications increased notably from 4.5 in 2001 to 14.4 million euros in 2014.
We highlight the market uptake of antidiabetic drugs commercialized during the last decade; despite further exploration is needed to clarify the cost-benefit ratio of these new antidiabetic medicines.
目前可用的抗糖尿病药物种类日益增多；然而，消费模式的变化仍缺乏充分记录。本研究的目的是分析2001年至2014年期间安达卢西亚某地区抗糖尿病药物的消费演变情况。
选取市场上所有的抗糖尿病药物进行分析。获取了15年期间的消费数据，并以每千居民每日限定日剂量（DDD）表示（DHD）。
在研究期间，胰岛素的消费量仅增长了2.2%，从17.9 DHD增至18.3 DHD，而口服药物增加了27.6%，从41.3 DHD增至52.7 DHD。磺脲类药物的消费量从30.1 DHD逐渐降至16.4 DHD，但二甲双胍（单独使用）的用量从4.3 DHD增至23.7 DHD，且在2014年是消费最多的药物。还注意到二肽基肽酶-4抑制剂和“其他降糖药物”的消费量有所上升。抗糖尿病药物的总支出从2001年的450万欧元显著增至2014年的1440万欧元。
我们强调了过去十年商业化的抗糖尿病药物的市场占有率；尽管需要进一步探究以阐明这些新型抗糖尿病药物的成本效益比。
